Sudden cardiac death and left ventricular ejection fraction during long-term follow-up after acute myocardial infarction in the primary percutaneous coronary intervention era: results from the HIJAMI-II registry

Shiga, Tsuyoshi; Hagiwara, Nobuhisa; Ogawa, Hiroshi; Takagi, Atsushi; Nagashima, Michitaka; Takao, Yoshinori; Tsurumi, Yukio; Koyanagi, Ryo; Kasanuki, Hiroshi

doi:10.1136/hrt.2008.145243

Cited by 94 publications

(69 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Left ventricular ejection fraction (LVEF) is one of the most important prognostic factors for survivors of MI. 1 Previous randomized trials introducing new therapeutic options for patients with AMI such as administration of β-blockers and angiotensin-converting enzyme (ACE) inhibitors have shown reduced morbidity and mortality with an LVEF increase of >3%. 2, 3 Despite previous intensive research, no drug has exceeded the effect of reperfusion by PCI to reduce infarct size in patients with AMI.…”

mentioning

confidence: 99%

Single-Dose Intravenous Administration of Recombinant Human Erythropoietin Is a Promising Treatment for Patients With Acute Myocardial Infarction

Ozawa

Toba

Suzuki

et al. 2010

Circ J

View full text Add to dashboard Cite

Background: Erythropoietin (EPO) has been found to have anti-apoptotic and tissue protective effects on the myocardium. The aim of the present pilot study was to observe the safety and efficacy of EPO administration for patients with acute myocardial infarction (AMI). Methods and Results:Patients admitted with AMI had all undergone successful percutaneous coronary intervention (PCI). Patients were randomly assigned to 2 groups (control and EPO groups), and given 12,000 IU EPO iv or saline after PCI. The primary endpoints were the difference between the acute phase and chronic phase (6 months after the attack) regarding left ventricular function as measured on electrocardiogram-gated single-photon emission computed tomography. Thirty-six patients (control 16, EPO 20) were eligible for analysis. Left ventricular ejection fraction (LVEF) significantly increased in the EPO group (from 51.0±19.6% to 58.5±15.0%, P=0.0238), but not in the control group. Further analysis was separately undertaken in patients with occlusion in the left anterior descending artery (LAD) and others (non-LAD). LVEF was <50% in most patients in the LAD subgroup, and LVEF significantly increased in the EPO group (37.5±13.0 to 52.7±15.8, P=0.0049), but not in the control group. EPO administration did not trigger any adverse clinical events.Conclusions: EPO administration is a promising treatment for AMI. (Circ J 2010; 74: 1415 - 1423

show abstract

mentioning

confidence: 99%

Single-Dose Intravenous Administration of Recombinant Human Erythropoietin Is a Promising Treatment for Patients With Acute Myocardial Infarction

Ozawa

Toba

Suzuki

et al. 2010

Circ J

View full text Add to dashboard Cite

show abstract

“…In our study, 86.4% of patients received early coronary revascularization during hospitalization due to acute MI. Currently, most patients with acute MI received early coronary revascularization, such as primary percutaneous coronary intervention, and a low incidence of SCD has been reported in patients with acute MI who receive primary percutaneous coronary intervention in the United States and Europe,29, 30 as well as in Japan 17…”

Section: Discussionmentioning

confidence: 99%

“…The HIJAMI‐II registry is an observational cohort study designed to determine the incidence of SCD according to the left ventricular ejection fraction (LVEF) in Japanese survivors of MI. The study design, objectives, and recruitment of study participants are described in detail elsewhere 17. Briefly, 4122 patients with acute MI who were discharged alive from 18 participating hospitals in Japan between 1999 and 2002 were enrolled immediately and were followed up for a mean period of 4.1 years.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Body Mass Index and Sudden Cardiac Death in Japanese Patients After Acute Myocardial Infarction: Data From the JCAD Study and HIJAMI‐II Registry

Shiga

Kohro

Yamasaki

et al. 2018

JAHA

View full text Add to dashboard Cite

BackgroundAlthough an “obesity paradox” exists in patients after myocardial infarction, the association between obesity and the risk of sudden cardiac death (SCD) is limited. The aim of this study was to determine whether obesity is associated with an increased risk of SCD in Japanese survivors of acute myocardial infarction.Methods and ResultsPooled data from 2 cohort studies in Japan, JCAD (Japanese Coronary Artery Disease) study and the Heart Institute of Japan Acute Myocardial Infarction‐II (HIJAMI‐II) registry, comprising of 6216 patients (mean age 65±11 years, 75.2% male) with acute myocardial infarction who were discharged alive, were studied. The patients were categorized into the following body mass index (BMI) groups at baseline according to the World Health Organization classification for Asian populations: BMI <18.5 kg/m2 (n=335), 18.5 to 23 kg/m2 (n=2371), 23 to 27.5 kg/m2 (n=2823), and ≥27.5 kg/m2 (n=687). The main outcomes were all‐cause mortality and SCD. During an average follow‐up period of 3.6±1.4 years, all‐cause mortality was 10.1%, and SCD was 1.2%. Patients with BMI <18.5 kg/m2 had the highest rate of all‐cause mortality (adjusted hazard ratio, 1.61; 95% confidence interval, 1.20–2.16), but high BMI (≥27.5 kg/m2) was not associated with mortality compared with patients in the group with BMI ≥18.5 and <23 kg/m2. However, the long‐term risk of SCD was increased in the group with BMI ≥27.5 kg/m2 (adjusted hazard ratio, 2.97; 95% confidence interval, 1.24–7.15). Multivariate analysis revealed that BMI ≥27.5 kg/m2 was associated with an increased risk of SCD (hazard ratio, 2.78; 95% confidence interval, 1.35–5.74).ConclusionsObesity (BMI ≥27.5 kg/m2) was associated with the risk of SCD in Japanese patients after myocardial infarction, although an obesity paradox was found for all‐cause mortality.

show abstract

“…4 The proportion of SCD (CPAOA) among the total deaths was 33% in this JCAD study, 13.3% in Tanno et al's study 16 and 12.1% in the HIJAMI-II study. 17 From these studies, the annual rate of SCD, as well as the proportion of SCD among all causes of death in OMI patients with LV dysfunction, was smaller in Japan than in Western countries, but possibilities to rescue considerably more OMI patients with LV dysfunction by implanting an ICD still exist in Japan.…”

Section: Angioplasty and LV Function In Patients With Omimentioning

confidence: 99%

Prognosis of Myocardial Infarction With Left Ventricular Dysfunction in the Coronary Revascularization Era

Kuga

Yamasaki

Hattori

et al. 2014

Circ J

View full text Add to dashboard Cite

Sudden cardiac death and left ventricular ejection fraction during long-term follow-up after acute myocardial infarction in the primary percutaneous coronary intervention era: results from the HIJAMI-II registry

Abstract: There is a low incidence of SCD in survivors of MI in the primary PCI era, although LVEF is a predictor of increased risk for SCD.

Cited by 94 publications

References 22 publications

Single-Dose Intravenous Administration of Recombinant Human Erythropoietin Is a Promising Treatment for Patients With Acute Myocardial Infarction

Single-Dose Intravenous Administration of Recombinant Human Erythropoietin Is a Promising Treatment for Patients With Acute Myocardial Infarction

Body Mass Index and Sudden Cardiac Death in Japanese Patients After Acute Myocardial Infarction: Data From the JCAD Study and HIJAMI‐II Registry

Prognosis of Myocardial Infarction With Left Ventricular Dysfunction in the Coronary Revascularization Era

Contact Info

Product

Resources

About